Puma Biotechnology Inc (NASDAQ:PBYI) insider Charles R. Eyler sold 1,322 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $105.46, for a total transaction of $139,418.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Puma Biotechnology Inc (NASDAQ:PBYI) traded down $4.40 during midday trading on Tuesday, reaching $93.85. 908,507 shares of the company’s stock were exchanged, compared to its average volume of 1,093,497. Puma Biotechnology Inc has a twelve month low of $28.35 and a twelve month high of $136.90.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) EPS for the quarter, beating analysts’ consensus estimates of ($2.50) by $0.43. The business had revenue of $6.10 million for the quarter, compared to the consensus estimate of $3.78 million. During the same quarter in the previous year, the business earned ($1.11) earnings per share. equities research analysts predict that Puma Biotechnology Inc will post -8.19 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of PBYI. Janus Henderson Group PLC bought a new position in Puma Biotechnology during the second quarter valued at approximately $162,302,000. Franklin Resources Inc. bought a new position in Puma Biotechnology during the second quarter valued at approximately $50,134,000. Point72 Asset Management L.P. grew its position in Puma Biotechnology by 265.6% during the third quarter. Point72 Asset Management L.P. now owns 482,200 shares of the biopharmaceutical company’s stock valued at $57,743,000 after acquiring an additional 350,300 shares during the last quarter. Bain Capital Public Equity Management LLC grew its position in Puma Biotechnology by 291.0% during the second quarter. Bain Capital Public Equity Management LLC now owns 338,994 shares of the biopharmaceutical company’s stock valued at $29,628,000 after acquiring an additional 252,294 shares during the last quarter. Finally, Perceptive Advisors LLC grew its position in Puma Biotechnology by 26.0% during the third quarter. Perceptive Advisors LLC now owns 923,820 shares of the biopharmaceutical company’s stock valued at $110,627,000 after acquiring an additional 190,500 shares during the last quarter. Institutional investors and hedge funds own 96.05% of the company’s stock.

Several research firms recently weighed in on PBYI. BidaskClub cut shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 14th. Credit Suisse Group upped their price objective on shares of Puma Biotechnology from $136.00 to $142.00 and gave the stock an “outperform” rating in a research report on Friday, November 10th. Barclays restated a “buy” rating and issued a $122.00 price objective (up from $103.00) on shares of Puma Biotechnology in a research report on Friday, November 10th. Citigroup upped their price objective on shares of Puma Biotechnology from $156.00 to $164.00 and gave the stock a “buy” rating in a research report on Friday, November 10th. Finally, Royal Bank Of Canada decreased their price objective on shares of Puma Biotechnology from $108.00 to $92.00 and set a “sector perform” rating on the stock in a research report on Friday, November 10th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $130.67.

TRADEMARK VIOLATION NOTICE: “Charles R. Eyler Sells 1,322 Shares of Puma Biotechnology Inc (PBYI) Stock” was reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/05/charles-r-eyler-sells-1322-shares-of-puma-biotechnology-inc-pbyi-stock.html.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Insider Buying and Selling by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.